Atai is a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications.
Atai is committed to acquiring and developing innovative mental health treatments that address significant unmet medical needs.
Atai was founded in 2018 by Christian Angermayer, alongside with Florian Bran and Srinivas Rao. The company is headquartered in Berlin, Germany, with offices in London, UK and New York City.
atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential.
Atai is backed by Apeiron Investment Group, Thiel Capital, Catalio Capital Management, Future Ventures, Galaxy Investment Partners, Falcon Edge Capital and others. The company raised $157M in a Series D round on Mar 03, 2021. This brings atai's total funding to $389.1M to date. The round reportedly valued atai at $2B post money.